PRIMARY HYPEROXALURIA TYPE 3

Clinical trials for PRIMARY HYPEROXALURIA TYPE 3 explained in plain language.

Never miss a new study

Get alerted when new PRIMARY HYPEROXALURIA TYPE 3 trials appear

Sign up with your email to follow new studies for PRIMARY HYPEROXALURIA TYPE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New hope for kids with rare kidney disease

Disease control Completed

This study tested a drug called nedosiran in children from birth to 11 years old who have primary hyperoxaluria, a rare genetic disease that causes kidney stones and can lead to kidney failure. The main goal was to see if the monthly treatment safely lowers the harmful oxalate le…

Matched conditions: PRIMARY HYPEROXALURIA TYPE 3

Phase: PHASE2 • Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company • Aim: Disease control

Last updated Mar 30, 2026 14:32 UTC

PRIMARY HYPEROXALURIA TYPE 3

Get alerted when new PRIMARY HYPEROXALURIA TYPE 3 trials appear

New hope for kids with rare kidney disease